CAH vs MBRX · P/E 35, rev $254.25B vs $8.2M cap
Cardinal Health Inc (CAH) versus Moleculin Biotech Inc (MBRX) — a side-by-side from cached financials, not a winner call.
Cardinal Health Inc (CAH) is a medical distribution company listed on NYSE.
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on US.
Latest reported CAH revenue for 2026-06-30 was $254.25B. Net income was $1.71B. Revenue was up 14.2% from 2025-06-30 to 2026-06-30. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
Latest reported MBRX revenue for 2026-06-30 was $0. Net income was -$20.5M. MBRX currently screens at market cap $8.2M.
CAH currently screens at market cap $53.00B and trailing P/E 34.6. MBRX currently screens at market cap $8.2M.
Not investment advice. Open the CAH and MBRX stock pages for the full models.
Not investment advice.